TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7564449
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of warm antegrade and retrograde delivery of cardioplegic solution (N = 25)
Study: 7023308
Drug: Digoxin treatment
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin treatment for 8 weeks
Study: 30613990
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster vaccine (4.3 log plaque-forming unit)
Study: 30613990
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster vaccine (4.7 log plaque-forming unit)
Study: 30613990
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster vaccine (4.9 log plaque-forming unit)
Study: 25407688
Drug: Zen meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zen meditation (MG) - meditated twice a day for 20 minutes for 3 months
Study: 25407688
Drug: Zen meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zen meditation (MG)
Study: 19692317
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG treatment (81 mg for 6 weeks)
Study: 8223740
Drug: Prazosin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.25 mg and 0.50 mg)
Study: 29713909
Drug: Rifaximin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (600 mg/day)
Study: 27435761
Drug: Capecitabine 1500
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1500 mg/daily continuously with rabeprazole 1.5 mg/kg twice a day, 3 days a week
Study: 27435761
Drug: Capecitabine 1500
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1500 mg/daily continuously without rabeprazole
Study: 20118792
Drug: Landiolol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (continuous administration during anesthesia)
Study: 15676092
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy (n=20)
Study: 15676092
Drug: Normothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia therapy (n=20)
Study: 11846857
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg twice/day for 6 days along with 0.4 mg digoxin on study day 5
Study: 28340244
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg/d for 7 days)
Study: 25469804
Drug: Candesartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (target dose 16 mg/d)
Study: 23884659
Drug: CJ leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ leflunomide 10 mg
Study: 23884659
Drug: CJ leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CJ leflunomide 20 mg
Study: 23884659
Drug: Arava® (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arava® (reference drug)
Study: 16870004
Drug: Hot skimmed
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot skimmed milk formulation (15 mg zeaxanthin)
Study: 16870004
Drug: Warm skimmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm skimmed milk formulation (15 mg zeaxanthin)
Study: 16870004
Drug: Hot water
Normalized name: hot water bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot water formulation (15 mg zeaxanthin)
Study: 10851837
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of vitamin A
Study: 9166880
Drug: Swallowing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing therapy with videoendoscopic biofeedback
Study: 21336727
Drug: Conventional swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional swallowing therapy
Study: 25978852
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg Folic Acid
Study: 25978852
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg Folic Acid
Study: 25978852
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Creatine
Study: 25978852
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Creatine + 400 μg Folic Acid
Study: 20433248
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with 0.03IU/mL felypressin
Study: 16750464
Drug: Nepafenac ophthalmic
Normalized name: nepafenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac ophthalmic suspension 0.03%
Study: 17621177
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium ophthalmic solution 0.1%
Study: 15142073
Drug: Vaseline applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline applied twice a day bilaterally for 4 weeks
Study: 11312048
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine into inflamed submucous tissue
Study: 11312048
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine into non-inflamed tissue
Study: 11312048
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine perineurally
Study: 9202804
Drug: Aerosolized furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized furosemide (2 mg/kg)
Study: 8187026
Drug: Inhaled phosphoramidon
Normalized name: phosphoramidic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled phosphoramidon (10(-5) M)
Study: 8187026
Drug: Inhaled NKA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NKA
Study: 25343850
Drug: Whey protein/fibre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein/fibre preload (17 g whey protein, 3 g lactose, 5 g guar, 1 g flavour material in 150 ml cold water)
Study: 25343850
Drug: Control (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (150 ml cold water with no additives)
Study: 23755872
Drug: 6 hours
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hours of daily patching
Study: 23755872
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching
Study: 1503519
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (hGH; 0.3 U/kg/24 hours)
Study: 6510453
Drug: Sustained-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release metoprolol (200 mg)
Study: 25781198
Drug: Arginine-based supplement
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine-based supplement (3.0 g of arginine, 300 mg of grape seed extract, and 300 mg of polyethylene glycol)
Study: 25781198
Drug: Arginine-based supplement
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine-based supplement
Study: 19542795
Drug: IVPCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVPCA morphine plus ketorolac (M+K group)
Study: 19542795
Drug: IVPCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVPCA morphine (M group)
Study: 9049514
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg b.d.
Study: 3524550
Drug: Intracervical PGF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical PGF2 alpha gel
Study: 8814744
Drug: Topical ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ganciclovir 0.15% gel
Study: 26671622
Drug: Topical 0.4%
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4% povidone-iodine solution
Study: 26671622
Drug: Preservative-free artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free artificial tears and topical antibiotics
Study: 31819619
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Study: 26093812
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus radiotherapy (IC+RT)
Study: 20528796
Drug: 500mL of
Normalized name: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL of 100% mandarin juice daily
Study: 15924512
Drug: Water-based exercise
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based exercise and self-management program (10-week duration, conducted twice a week for one hour)
Study: 8788291
Drug: High-lipase enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-lipase enteric-coated microsphere preparation
Study: 8788291
Drug: Low-lipase enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lipase enteric-coated microsphere preparation
Study: 6218815
Drug: 5% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% (w/v) benzoyl peroxide gel
Study: 6218815
Drug: 1.5% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% (w/v) erythromycin lotion
Study: 23225539
Drug: Amitriptyline (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (high-dose level)
Study: 21858807
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals)
Study: 20048654
Drug: Single-injection ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection ultrasound-guided infraclavicular block
Study: 20048654
Drug: Double-injection ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection ultrasound-guided infraclavicular block
Study: 20048654
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as the single-injection group)
Study: 15906589
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine formulation A (21 mg/day)
Study: 15906589
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine formulation B (21 mg/day)
Study: 9861122
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg i.v. followed by infusion at a rate of 90 mg/15.5 h
Study: 9861122
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg followed by infusion of 75 mg/15.5 h
Study: 9861122
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg followed by infusion of 100 mg/15.5 h
Study: 25727941
Drug: Corn silk
Normalized name: CORN SILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn silk aqueous extract (60, 130, 192.5 and 260 mg/kg body weight)
Study: 17238221
Drug: Current drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current drug treatment
Study: 17238221
Drug: Alternative hypothetical
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative hypothetical drug
Study: 17238221
Drug: No preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preventive medication
Study: 14667152
Drug: Melatonin (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1.8 mg sustained release)
Study: 14667152
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intermittent bright light, dark sunglasses, and regular early daytime dark/sleep period
Study: 10612322
Drug: Statin drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drug treatment
Study: 6144522
Drug: Clorazepate 15
Normalized name: clorazepate 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate 15 mg nocte
Study: 6144522
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg t.d.s.
Study: 18074761
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (control)
Study: 27484801
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy plus trastuzumab, lapatinib or both
Study: 26162993
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells (WJMSCs)
Study: 23412022
Drug: Cosmetic slimming
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic slimming treatment (twice a day for 4 weeks)
Study: 20303209
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment with rigid maxillomandibular fixation
Study: 15708387
Drug: Ivermectin high
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin high dose (800 microg/kg) given three-monthly
Study: 15708387
Drug: Ivermectin standard
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin standard dose (150 microg/kg) given annually
Study: 15708387
Drug: Ivermectin high
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin high dose (800 microg/kg) given annually
Study: 12906959
Drug: Two simultaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two simultaneously consumed 400 microg OTFC doses
Study: 12906959
Drug: One 800
Normalized name: metaxalone 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 800 microg OTFC dose
Study: 10543484
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (HC), n = 14
Study: 8912225
Drug: Cumulative dose-response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cumulative dose-response curve
Study: 8912225
Drug: Noncumulative dose-response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Noncumulative dose-response curve
Study: 1841573
Drug: Serologic studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serologic studies (antinuclear antibody test, fluorescent treponemal antibody absorption test)
Study: 31187261
Drug: Iron picolinate
Normalized name: iron picolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron picolinate (2.5 mg 57Fe per serving, two servings)
Study: 31187261
Drug: Iron sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron sulfate (2.5 mg 54Fe per serving, two servings)
Study: 31187261
Drug: Relative bioavailability
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative bioavailability of Fe picolinate versus Fe sulfate
Study: 30378695
Drug: Alpinia officinarum
Normalized name: ALPINIA OFFICINARUM LEAF
DrugBank: Alpinia officinarum leaf (DB15789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpinia officinarum extract (300 mg daily for 3 months)
Study: 26629352
Drug: Proteinuria <0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteinuria <0.7 g/day after 12 months of treatment
Study: 4041332
Drug: LA propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA propranolol 160 mg
Study: 4041332
Drug: LA propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA propranolol 320 mg
Study: 4041332
Drug: LA propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA propranolol 160 mg and 320 mg
Study: 27974693
Drug: Nimotuzumab with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab with concurrent chemotherapy and radiotherapy
Study: 26836793
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 mg twice daily)
Study: 19966341
Drug: Warfarin (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted to INR 2.0 to 3.0)
Study: 10567779
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg, p.o., once daily)
Study: 8584455
Drug: Spirulina fusiformis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina fusiformis (1 g/day for 12 months)
Study: 25681068
Drug: Dalbavancin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin 1000 mg intravenous (i.v.)
Study: 25681068
Drug: Dalbavancin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin 1500 mg intravenous (i.v.)
Study: 25681068
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous (i.v.)
Study: 21733508
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus combined hormonal oral contraceptive (OC)
Study: 14609531
Drug: Ginger extract
Normalized name: ginger extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract (Zintona EC) 250 mg of Zingiberis Rhizoma per capsule, qid
Study: 3963032
Drug: Buspirone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (all doses)
Study: 22240397
Drug: Tri‐antigen combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri‐antigen combination of rApxIA, rApxIIA and rApxIIIA
Study: 22240397
Drug: Hexa‐antigen vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexa‐antigen vaccine containing rApfA
Study: 22240397
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with rApfA alone or in combination with other antigens
Study: 20175977
Drug: tramadol/acetaminophen 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol/acetaminophen 37.5 mg/325 mg
Study: 18771003
Drug: Azelnidipine 8
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 8 mg
Study: 12675275
Drug: Azelnidipine 16
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 16 mg
Study: 18771003
Drug: Azelnidipine 8
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 8 mg, q.d. (multiple doses)
Study: 12524662
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement for 8 weeks
Study: 12524662
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement for 40 weeks
Study: 10783995
Drug: Intravenous L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-arginine (500 mg/kg body weight/120 min)
Study: 8115696
Drug: Naloxone 2
Normalized name: naloxone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 2 mg
Study: 6835887
Drug: Hyoscine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine 1.6 mg
Study: 30688135
Drug: Pregabalin 10
Normalized name: pregabalin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 10 mg/kg/d
Study: 30688135
Drug: Pregabalin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 2.5 mg/kg/d
Study: 22047669
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy Competence Scale for Social Phobia (CTCS-SP)
Study: 20578869
Drug: Chin cup
Normalized name: CHIN-UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin cup with 600 g of force per side (Group 1, n = 20)
Study: 20578869
Drug: Chin cup
Normalized name: CHIN-UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chin cup with 300 g of force per side (Group 2, n = 20)
Study: 20578869
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 3, n = 10)
Study: 15699762
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (3 g/day, n=36)
Study: 15699762
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir (8 g/day, n=35)
Study: 15699762
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (n=12)
Study: 11909906
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADL) scores
Study: 29910030
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg once daily added to ezetimibe 10 mg/day for 12 weeks
Study: 29910030
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to ezetimibe 10 mg/day for 12 weeks
Study: 22866693
Drug: Culturally accommodated
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally accommodated cognitive-behavioral treatment (A-CBT)
Study: 22866693
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral treatment (S-CBT)
Study: 28303530
Drug: BTH1677 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTH1677 (4 mg/kg, weekly) + cetuximab (initial dose 400 mg/m2, subsequent doses 250 mg/m2, weekly) + carboplatin (6 mg/mL/min AUC, Q3W) + paclitaxel (200 mg/m2, Q3W)
Study: 25601916
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g acetyl-l-carnitine for 12 weeks